WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406381
CAS#: 91300-60-6
Description: LY83583 is a Msp1 inhibitor, a guanylate cyclase inhibitor and a cGMP modulator. LY83583 inhibits soluble guanylate cyclase in human platelets with an IC50 value of 2 µM. LY83583 also inhibits leukotriene synthesis in guinea pig lung and rat peritoneal cells with an IC50 value of 1.8 µM and is a noncompetitive inhibitor of glutathione reductase in bovine intestinal mucosa with a Ki value of 3 µM.
Hodoodo Cat#: H406381
Name: LY83583
CAS#: 91300-60-6
Chemical Formula: C15H10N2O2
Exact Mass: 250.07
Molecular Weight: 250.257
Elemental Analysis: C, 71.99; H, 4.03; N, 11.19; O, 12.79
Synonym: LY83583; LY-83583; LY 83583. LY83583; LY-83583; LY 83583.
IUPAC/Chemical Name: 6-(phenylamino)quinoline-5,8-dione
InChi Key: GXIJYWUWLNHKNW-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H10N2O2/c18-13-9-12(17-10-5-2-1-3-6-10)15(19)11-7-4-8-16-14(11)13/h1-9,17H
SMILES Code: O=C(C(NC1=CC=CC=C1)=C2)C3=C(N=CC=C3)C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 250.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Tsuda K, Nishiya N, Umeyama T, Uehara Y. Identification of LY83583 as a specific inhibitor of Candida albicans MPS1 protein kinase. Biochem Biophys Res Commun. 2011 Jun 10;409(3):418-23. doi: 10.1016/j.bbrc.2011.05.010. Epub 2011 May 8. PubMed PMID: 21586273.
2: Lodygin D, Menssen A, Hermeking H. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest. 2002 Dec;110(11):1717-27. PubMed PMID: 12464677; PubMed Central PMCID: PMC151636.
3: Kumagai Y, Midorikawa K, Nakai Y, Yoshikawa T, Kushida K, Homma-Takeda S, Shimojo N. Inhibition of nitric oxide formation and superoxide generation during reduction of LY83583 by neuronal nitric oxide synthase. Eur J Pharmacol. 1998 Nov 6;360(2-3):213-8. PubMed PMID: 9851588.
4: Leinders-Zufall T, Zufall F. Block of cyclic nucleotide-gated channels in salamander olfactory receptor neurons by the guanylyl cyclase inhibitor LY83583. J Neurophysiol. 1995 Dec;74(6):2759-62. PubMed PMID: 8747232.
5: Luo D, Das S, Vincent SR. Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol. 1995 Aug 15;290(3):247-51. PubMed PMID: 7589219.
6: Lee YS, Wurster RD. Mechanism of potentiation of LY83583-induced growth inhibition by sodium nitroprusside in human brain tumor cells. Cancer Chemother Pharmacol. 1995;36(4):341-4. PubMed PMID: 7628054.
7: Feng CJ, Cheng DY, Kaye AD, Kadowitz PJ, Nossaman BD. Influence of N omega-nitro-L-arginine methyl ester, LY83583, glybenclamide and L158809 on pulmonary circulation. Eur J Pharmacol. 1994 Sep 22;263(1-2):133-40. PubMed PMID: 7821344.
8: Lüönd RM, McKie JH, Douglas KT. A direct link between LY83583, a selective repressor of cyclic GMP formation, and glutathione metabolism. Biochem Pharmacol. 1993 Jun 22;45(12):2547-9. PubMed PMID: 8101080.
9: Sundqvist T, Axelsson KL. The cGMP modulator, LY83583 alters oxygen metabolites differently in cultured endothelial cells and isolated neutrophilic granulocytes. Pharmacol Toxicol. 1993 Mar;72(3):169-74. PubMed PMID: 8390653.
10: Kontos HA, Wei EP. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke. 1993 Mar;24(3):427-34. PubMed PMID: 8095358.
11: Axelsson KL, Ahlner J, Torfgård K. Effect of pertussis toxin and the cGMP lowering agent LY83583 on the relaxation induced by nitrates in isolated bovine mesenteric artery. A comparison between glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate. Z Kardiol. 1989;78 Suppl 2:11-3; discussion 64-7. PubMed PMID: 2555977.
12: Malta E, Macdonald PS, Dusting GJ. Inhibition of vascular smooth muscle relaxation by LY83583. Naunyn Schmiedebergs Arch Pharmacol. 1988 Apr;337(4):459-64. PubMed PMID: 2900475.
13: Diamond J. Effects of LY83583, nordihydroguaiaretic acid, and quinacrine on cyclic GMP elevation and inhibition of tension by muscarinic agonists in rabbit aorta and left atrium. Can J Physiol Pharmacol. 1987 Sep;65(9):1913-7. PubMed PMID: 2825946.
14: MacLeod KM, Diamond J. Effects of the cyclic GMP lowering agent LY83583 on the interaction of carbachol with forskolin in rabbit isolated cardiac preparations. J Pharmacol Exp Ther. 1986 Jul;238(1):313-8. PubMed PMID: 3014120.
15: Diamond J, Chu EB. A novel cyclic GMP-lowering agent, LY83583, blocks carbachol-induced cyclic GMP elevation in rabbit atrial strips without blocking the negative inotropic effects of carbachol. Can J Physiol Pharmacol. 1985 Aug;63(8):908-11. PubMed PMID: 3000562.
16: Schmidt MJ, Sawyer BD, Truex LL, Marshall WS, Fleisch JH. LY83583: an agent that lowers intracellular levels of cyclic guanosine 3',5'-monophosphate. J Pharmacol Exp Ther. 1985 Mar;232(3):764-9. PubMed PMID: 2857787.
